Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Mohamed Sabbah; Stephanie Nguyen; Maya Ouzegdouh; Sylvain Choquet; David Buob; Jean Jacques Boffa; Alexandre Cez; Laurent Garderet

doi:10.12659/AJCR.944681

01 November 2024 : Case report France

Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Unusual clinical course, Challenging differential diagnosis

Mohamed Sabbah^1ABCDEF, Stephanie Nguyen^1ACDE, Maya Ouzegdouh^1ADE, Sylvain Choquet^1ADE, David Buob^2BDE, Jean Jacques Boffa^3ADE, Alexandre Cez^3ADE, Laurent Garderet^4ABCDEF*

DOI: 10.12659/AJCR.944681

Am J Case Rep 2024; 25:e944681

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Light microscopy image of the patient’s renal biopsy showing focal segmental glomerulosclerosis not otherwise specified (FSGS NOS) with sclerosis, hyalinosis, adhesion, and slight podocyte hyperplasia (arrow) (hematoxylin and eosin staining (A) and periodic acid-Schiff staining, ×100 (B)).

Back to the Article

Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Your Privacy